Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: A multicenter prospective study

Journal of Infection and Chemotherapy

Volumn 20, Issue 1, 2014, Pages 30-34

  Endo, Shigeatsu ^a   Suzuki, Yasushi ^a   Takahashi, Gaku ^a   Shozushima, Tatsuyori ^a   Ishikura, Hiroyasu ^b   Murai, Akira ^b   Nishida, Takeshi ^b   Irie, Yuhei ^b   Miura, Masanao ^c   Iguchi, Hironobu ^c   Fukui, Yasuo ^d   Tanaka, Kimiaki ^d   Nojima, Tsuyoshi ^d   Okamura, Yoshikazu ^e  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c Toyota Kai Medical Corporation Kariya Toyota General Hospital   (Japan)

^d Kochi Health Sciences Center   (Japan)

^e LSI MEDIENCE CORPORATION   (Japan)

Author keywords

APACHE 2 score; Presepsin; Procalcitonin; PrognosiS.; SepsiS.; SOFA score

Indexed keywords

BINDING PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 6; PRESEPSIN; PROCALCITONIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CD14 ANTIGEN;

AGED; APACHE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT MONITORING; PROGNOSIS; PROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; BLOOD; CLINICAL TRIAL;

AGED; ANTIGENS, CD14; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS;

EID: 84903724768     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2013.07.005     Document Type: Article

References (21)

1. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707e10. (Pubitemid 26254283)
2. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE 2: a severity of disease classification system. Crit Care Med 1985;13:818e29. (Pubitemid 15250137)
3. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002;323:17e29. (Pubitemid 34804792)
4. Aikawa N, Fujishima S, Endo S, Sekine I, Kogawa K, Yamamoto Y, et al. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 2005;11:152e9. (Pubitemid 40933683)
5. Endo S, Aikawa N, Fujishima S, Sekine I, Kogawa K, Yamamoto Y, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother 2008;14:244e9. (Pubitemid 351875922)
6. Endo S, Sato N, Suzuki Y, Kojika M, Takahashi G, Yamada Y, et al. Significance of measuring procalcitonin values for diagnosis of sepsis. J Jpn Soc Surg Infect 2007;4:112e20 [in Japanese].
7. Furusako S, Shirakawa K. Methods for detecting human low molecular weight CD14. United States patent 2008;US7465547 B2.
8. Furusako S, Shirakawa K, Hirose J. Soluble CD14 antigen. United States patent 2009;US7608684 B2.
9. Naitoh K, Shirakawa K, Hirose J, Nakamura M, Takeuchi T, Hosaka Y, et al. The new sepsis marker, sCD14-ST (PRESEPSIN), induction mechanism in the rabbit sepsis models. SEPSIS 2010. poster:P-19.
10. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005;11:234e8. (Pubitemid 41570019)
11. Kojika M, Takahashi G, Matsumoto N, Kikkawa T, Hoshikawa K, Shioya N, et al. Serum levels of soluble CD14 subtype reflect the APACHE 2 and SOFA scores. Med Postgrad 2010;48:46e50.
12. Takahashi G, Suzuki Y, Kojika M, Matsumoto N, Shozushima T, Makabe H, et al. Evaluation of responses to IVIG therapy in patients with severe sepsis and septic shock by soluble CD14 subtype monitoring. Med Postgrad 2010;48: 19e24.
13. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011;17:764e9.
14. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. The usefulness of presepsin as the diagnosis of sepsis in the multicenter prospective study. J Infect Chemother 2012;18:891e7.
15. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644e55.
16. Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem 2008;375:144e6.
17. Okamura Y, Yokoi H. Development of a point-of-care assay system for easurement of presepsin (sCD14-ST). Clin Chim Acta 2011;412:2157e61.
18. Meisner M. Procalcitonin: erfahrungen mit einer neuen messgroesse fuer bakterielle infektionen und systemische inflammation. J Lab Med 1999;23:263e72. (Pubitemid 29255495)
19. Clec'h C, Ferriere F, Karoubi P, Fosse JP, Cupa M, Hoang P, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004;32(5):1166e9. (Pubitemid 38620986)
20. Pettilä V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002;28(9):1220e5. (Pubitemid 35025038)
21. Gibot S, Cravoisy A, Kolopp-Sarda MN, Béné MC, Faure G, Bollaert PE, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005;33(4):792e6.